The New York-based startup Epibone intends to begin human testing on a procedure that will utilize stem cells to regenerate living bone tissue. The researchers, originally from Columbia University, will apply autologous [the patient’s own] stem cells to nanofiber scaffolding of the desired size and shape and direct the stem cells to differentiate into a physical and genetic replica of the patient’s own bone.
Topics: osteoporosis, limbs, Fingers, Jaw, Bone loss, stemsaveblog, Joints, Bone, Debilitating Diseases, Arthritis, Stemcells, Knee, hip, autologousstemcells, cartilage, grants, Mandibular bone, young stem cells
According to new research from the National Yang-Ming University, mesenchymal stem cells [MSCs] hold the ability to limit atherosclerotic plaque formation, thereby preventing the onset of harmful endothelial lesions. The research team, led by Shih-Chieh Hung, transplanted MSCs into animal models with atherosclerosis and observed significant reduction in plaque formation. They also saw an increase in blood vessel dilation, which prevents further plaque development, indicating good endothelial health.
In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells. The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well.
A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans. 27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection.
Topics: limbs, Phase III, traumatic brain injuries, neural stem cells, multiple sclerosis, stemsaveblog, clinical trials, Debilitating Diseases, Phase II, Stemcells, autologousstemcells, Neurodegenerative disease
Doctors and Scientist at the Southampton General Hospital have successfully completed a hip transplant by using a titanium socket and a bone scaffold loaded with skeletal stem cells. The team, led by orthopedic surgeon Douglas Dunlap, 3D printed the titanium implant, and then added the bone graft filled with stem cells to the pelvis to encourage bone regrowth behind and around the metal replacement.
Immunologists at the Medical College of Georgia and College of Dental Medicine a Georgia Regents University have developed a method of utilizing autologous [the patient’s own] stem cells to treat Ischemia Reperfusion Injury, a condition in which excessive blood flow to an injury results in severe inflammation and hindered recovery. The stem cells function with a chemical called indoleomine 2,3 Dioxygenase, or IDO, which can regulate the immune response without completely disabling it, allowing the healing process to ensue normally.
A research team led by Stephen Badylak at the University of Pittsburgh has used the patient’s own stem cells to help them recover from injuries in which over 50% of their leg muscle was lost. First, they implanted a biological scaffold into the wound. Then, the patients underwent aggressive physical therapy, which directed the recruitment of stem cells to the site of injury to rebuild properly aligned muscle tissue. By the end of the treatment, patients exhibited muscle regrowth and at least a 20% increase in leg strength.
Researchers at Johns Hopkins University, Department of Plastic and Reconstructive Surgery find that mesenchymal stem cells [the type of stem cells found in teeth] promoted nerve regeneration in animal models [in this case - rodents] with paralyzing leg injuries. According to the researchers, "Mesenchymal stem cells may be a promising add-on therapy to help damaged nerves regenerate.” The study found that the rodents treated with their own stem cells responded best to the treatment. Those treated with donated cells from dissimilar rodent types – a situation most similar to human transplants – rejected their new limbs.